In the current era, would a positive treat-to-target study in AS change your approach to practice? (TICOSPA trial ABST1444) #ACR20 @RheumNow

Check out my video on T2T in SpA abstracts from #ACR20 @RheumNow https://t.co/ZBvmhWyDHU

• Treat to Target in Spondyloarthritis: Dr. Rachel Tate | RheumNow

Network Meta-Analysis of JAK and TNF Inhib in 19 AS studies (3,654pts) showed best results with TNFi (golimumab and infliximab) but JAKs also appear to be effective option. #ACR20 Abstr#1357 #UTSW @AdelaCastro222 https://t.co/HnnPD6eXW5 https://t.co/Li30kkp3P1

• https://meet.acrconvergence.org/meetings/virtual/wtv3TtGdj9h5scjeN

RheumNow’s expanded coverage of the annual #ACR2020 meeting is sponsored in part by @bmsnews, @HorizonNews, @SanofiGenzyme, @Novartis. All content chosen by RheumNow & its Faculty.

axSpA patients have higher rates of c-section,  pre-eclampsia, IUGR and fetal complications vs normal population. Findings from a meta-analysis/systematic review #ABS1323 #ACR20 @RheumNow https://t.co/Ya9r0td7Ev https://t.co/miNURP6bOK

• Pregnancy in Axial Spondyloarthropathy: A Systematic Review & Meta-Analysis…

Distinct gut microbiome in Ankylosing Spondylitis and AS-IBD patients compared with IBD and healthy controls. 1⃣Different alpha and beta-diversity in AS pts vs. IBD 2⃣TNFi use ➡️differentiation microbiome in IBD pts @RheumNow #ACR20 Abs#1310 https://t.co/AGZbJZ9jtR

Both fat mass and fat free mass have an impact on the response to bDMARDs after 6 months of treatment in AS pts. No tx response changes w/ skeletal muscle mass, visceral fat as well as water components. #ABS1376 #ACR20 @RheumNow https://t.co/oIdE8qvJPp https://t.co/wlXFf8esey

• Impact of Body Composition Measures on the Response to Biological Disease-modif…

In patients with Crohn's disease (CD), the presence of HLA-B27 and higher clinical activity of CD were associated with presence of SpA. SpA was present in 21% of early CD patients @RheumNow #ACR20 Abstr#1308